Compare LyondellBasell Industries NV (LYB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs State Street SPDR S&P Biotech ETF — how do they compare? LyondellBasell Industries NV trades at $61.41 (market cap $19.60B), while State Street SPDR S&P Biotech ETF trades at $154.07. The key difference: LyondellBasell Industries NV pays a 6.78% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, LyondellBasell Industries NV nearer its low. Which is the better fit depends on your goals.
| LYB | XBI | |
|---|---|---|
Market Cap | $19.60B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $82.38 | $164.28 |
52-Week Low | $42.28 | $85.16 |
Enterprise Value | $31.22B | — |
Dividend Yield | 6.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.78, up 2.69% today, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals: revenue declined to $30.15B in 2025 with a net loss of $745M, yet valuation ratios like P/S of 0.64 appear attractive. Recent news highlights partnerships for sustainable packaging, while cash flow remains positive. Analysts are divided with a consensus price target of $73.11, suggesting 20% upside potential from current levels.
Outlook: LYB offers value appeal with low P/S and dividend yield, but faces profitability challenges and industry headwinds. Risks include volatile earnings and high debt. The stock is suitable for value investors tolerant of cyclical downturns, with catalysts from restructuring and sustainability initiatives.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
